ChromaDex Corporation (CDXC) Q3 2024 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call highlights strong financial performance with a 31% revenue increase and improved margins. Despite some risks like competitive pressures and regulatory challenges, the company shows a positive cash flow and no debt. The Q&A reveals plans for expansion and positive consumer response to Niagen. The lack of specific shareholder return plans is a slight negative. Overall, the positive financials and optimistic market strategy suggest a stock price increase, likely in the 2% to 8% range.
Key Financial Performance
Revenue $25.6 million, a 31% increase year-over-year, driven by a 368% increase in Niagen ingredient sales and 16% growth in e-commerce sales.
Net Income $1.9 million, compared to a net loss of $1 million in Q3 2023, an improvement of $2.9 million due to higher net sales and gross margin improvements.
Adjusted EBITDA $2.9 million, marking the sixth consecutive quarter of positive adjusted EBITDA.
Cash Flow Total positive cash flow of $5.1 million for the quarter.
Gross Margin 63.5%, up 210 basis points from 61.4% in Q3 2023, driven by changes in product mix and improvements in labor and overhead utilization rates.
Operating Income $1.6 million, an improvement of $2.7 million compared to a loss of $1.1 million in Q3 2023, driven by higher net sales and gross margin improvements.
Cash Position $32.4 million in cash and no debt at the end of the quarter.
Selling and Marketing Expenses 27.5% of net sales, improved from 31% in Q3 2023, reflecting strategic scaling of investments.
Research and Development Expenses Stable year-over-year, focusing on advancing innovations.
General and Administrative Expenses Increased by $0.5 million year-over-year due to higher legal expenses.
Net Cash Provided by Operations $3.5 million for the nine months ended September 30, 2024, compared to $6.5 million in the same period last year, largely driven by changes in working capital.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
New Product Launch: Launched Niagen Plus product line, including Niagen IV and injections at select clinics, expanding to over 100 clinics and expecting to reach over 300 clinics soon.
Sales Growth of New Product: Initial sales of pharmaceutical grade Niagen contributed to $14.8 million in revenue for the Niagen ingredient business, a 16% growth year-over-year.
Market Expansion: E-commerce growth driven by marketing efforts, particularly on Amazon, and improvements on the company's website.
Strategic Partnerships: Collaboration with Watsons for marketing initiatives to enhance customer acquisition and retention.
Operational Efficiency: Gross margins improved to 63.5%, up 210 basis points year-over-year, driven by product mix changes and improved labor and overhead utilization.
Financial Performance: Achieved record revenue of $25.6 million, a 31% increase year-over-year, and positive adjusted EBITDA of $2.9 million.
Leadership Change: Appointment of Ozan Pamir as new CFO to strengthen financial discipline and pursue strategic entry into the pharmaceutical sector.
Regulatory Strategy: Initiated communication with the FDA for investigational new drug application for nicotinamide riboside in treating ataxia telangiectasia.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Competitive Pressures: ChromaDex faces competition from brands offering NAD boosting products that do not meet their claims, which could impact market share and consumer trust.
Regulatory Issues: The company is pursuing an investigational new drug IND application for nicotinamide riboside, which involves navigating FDA regulations and potential delays.
Supply Chain Challenges: Sales to Watsons have been impacted by a decline in the Hong Kong retail market, indicating potential supply chain and distribution challenges.
Economic Factors: Global market and economic conditions could affect ChromaDex's business operations and financial results, as mentioned in their risk factors.
Legal Expenses: Increased legal expenses related to the Niagen Plus launch and patent defense litigation may impact overall profitability.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Growth: Achieved record results with $25.6 million in revenue, a 31% increase year-over-year.
E-commerce Growth: E-commerce business growth was a cornerstone, with stronger trends on Amazon and the company's website.
Niagen Plus Launch: Launched Niagen Plus product line, expanding to over 300 clinics in the coming weeks.
FDA Communication: Initiated communication with the FDA for investigational new drug application for nicotinamide riboside.
Marketing Initiatives: Collaborating with Watsons on marketing initiatives to enhance customer acquisition and retention.
Leadership Transition: Appointment of Ozan Pamir as new CFO to guide growth and financial discipline.
2024 Revenue Outlook: Expecting approximately 15% year-over-year growth in net sales.
Gross Margin Expectations: Expecting strong and steady gross margins with slight improvement over the prior year's 60.8%.
Investment Plans: Plans to invest in sales and marketing during Q4 to support Niagen IV launch.
R&D Investments: Increasing research and development investments to support core strategic initiatives.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Shareholder Return Plan: ChromaDex Corporation has not announced any specific share buyback program or dividend program during the Q3 2024 earnings call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Could you talk a little bit about the formulations now, both IV and injectable?
A:It's in 100 clinics today, and we expect it to be in about 300 within the next few weeks. Most people who are going in for Niagen IV are getting 500 milligrams.
Q:Could you clarify the $6.4 million you mentioned?
A:That was just the improvement we had in the net income, the $6.4 million. The cash provided by operations was $3.5 million.
Q:Could you talk about the ataxia orphan indication and what we may look forward to in 2025?
A:We're having conversations with the FDA. We hope to get their notes on our pre-IND submission within a month.
Q:What's the pricing like for a single dose of Niagen?
A:The pricing of Niagen IV is generally between $500 and $700 per session.
Q:Do you see further improvements in margins through 2025?
A:As Niagen Plus grows, that will have a positive impact on gross margins.
Q:What is the biggest restraint on growing the number of clinics?
A:The only real restraint we have at this point is supply of material.
Q:How are patients responding to Niagen?
A:The majority of consumers thus far have been converts from NAD, and they're having an extremely positive experience.
Q:Will growth in 2025 be higher than in 2024?
A:It's too early for us to say.
Q:Is there something in the food-grade Niagen that's related to the pharmaceutical?
A:The food-grade Niagen is up due to a customer initiating an Amazon sales strategy.
Q:How would 500 milligrams of Niagen Plus compare to Tru Niagen capsules?
A:Our scientists are still studying the long-term differential.
Q:Will you be able to market Niagen Plus with the new data?
A:We intend to.
Q:How large is the addressable market for clinics?
A:We estimate the addressable market for clinics that deliver IV to be around 3,000.
Q:Review of Unclear Management Responses
A:Management appeared to avoid giving a direct answer regarding the growth forecast for 2025, stating it's too early to say.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
CFO
ChromaDex phase
ChromaDex year
Cohen Ladenburg
FDA
Finance
Hi
IND
IV NAD
IV therapy
NAD IV
Pamir
Plus IV
Plus product
advancement
awareness
bloodstream
celebrity
clinic IV
credit
decline
experience
food grade
hour
improvement income
initiative
injection
lot
marketing effort
people
pharma
pharmaceutical
place
restraint
sale commerce
session
treatment
vertical
website
week
CDXC Transcript
ChromaDex Corporation (NASDAQ:CDXC) Q4 2024 Earnings Call Transcript
Positive3-5
The company reported record revenue growth and strong e-commerce performance, which are positive indicators. Despite some supply chain issues, management remains optimistic about growth, especially with the Niagen IV expansion and potential partnerships. The Q&A revealed uncertainties in the NO PARK study and NAD+ testing, but these were not major concerns. Overall, the positive revenue outlook and strong product development outweigh the minor uncertainties, suggesting a positive stock price movement in the near term.
Earnings call transcript: Chromadex’s Q4 2024 earnings beat forecasts, stock rises
Positive3-4
The earnings call shows strong financial performance with record revenues, significant net income growth, and improved margins. The e-commerce channel and NIAGEN ingredient sales have also seen substantial increases. While there are uncertainties in R&D outcomes, the overall financial health and strategic product launches suggest a positive outlook. The Q&A section did not reveal major concerns that would offset these positives. Despite the lack of a share repurchase program, the company's cash flow and debt-free status support a positive sentiment.
ChromaDex Corporation (CDXC) Q3 2024 Earnings Call Transcript
Positive11-1
The earnings call highlights strong financial performance with a 31% revenue increase and improved margins. Despite some risks like competitive pressures and regulatory challenges, the company shows a positive cash flow and no debt. The Q&A reveals plans for expansion and positive consumer response to Niagen. The lack of specific shareholder return plans is a slight negative. Overall, the positive financials and optimistic market strategy suggest a stock price increase, likely in the 2% to 8% range.
ChromaDex Corporation (CDXC) Q3 2024 Earnings Call Transcript
Positive8-8
The earnings call highlights strong financial performance with a 31% revenue increase and improved margins. Despite some risks like competitive pressures and regulatory challenges, the company shows a positive cash flow and no debt. The Q&A reveals plans for expansion and positive consumer response to Niagen. The lack of specific shareholder return plans is a slight negative. Overall, the positive financials and optimistic market strategy suggest a stock price increase, likely in the 2% to 8% range.
CDXC Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
